Bulls, Bears and the Bell | CPI Countdown, AI Capex Supercycle, and the Biotech Binary Play

Welcome to Bulls, Bears and the Bell, your essential pre-market macro and equity briefing for Wednesday, August 12, 2026.In today's high-stakes episode, anchors Joe and Jane break down what is shaping up to be the most critical trading session of the month. We are counting down to the make-or-break July Consumer Price Index (CPI) print at 8:30 AM ET. With forecasts pointing to 3.4% headline YoY and 2.5% core YoY, we discuss whether a hot print will validate the Fed's hawkish dissenters or if a cool print will pave the way for a September cut. This critical inflation checkpoint arrives on the heels of a labor market showing a shocking contraction of 23,000 jobs in the latest payrolls report.Here is what we are covering before the opening bell rings:Global Market Snapshot: S&P 500 futures trading up 0.35% and Nasdaq 100 futures leading at +0.52%. We also dive into Tokyo’s overnight resilience as the global memory boom continues to lift the Nikkei 225.Top Pre-Market Movers: The ultimate binary play in NeOnc Technologies (NTHI) as they release highly-anticipated Phase 2a brain cancer data at 8:30 AM ET. We also check in on Intel's (INTC) ongoing 140% year-over-year turnaround and Micron (MU) as persistent AI data center demand drives the 2026 memory shortage.Macro Assets & Physical AI: Why Gold is holding firm above $4,300 as the ultimate hedge, and how the massive AI Capex Supercycle is fueling a projected $975 billion semiconductor market this year.Subscribe on Spotify or your favorite podcast app to make sure you never miss a pre-market update!DisclaimerThe financial information, stock analysis, and economic forecasts presented in this podcast are based entirely on the pre-market research report dated Wednesday, August 12, 2026. This content is for educational and informational purposes only and does not constitute investment, financial, legal, or tax advice. Trading equities, futures, and volatile clinical-stage biotechnologies involves a high level of risk and may not be suitable for all investors. Always perform your own due diligence before making investment decisions.